ArticleTherapeutic advances in gastroenterology2021

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.

Davide Massimi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.